In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary

xaliproden hydrochloride  
The hydrochloride salt of xaliproden, an orally-active, synthetic, non-peptidic 5-hydroxytryptamine (5-HT) 1A receptor agonist with neurotrophic and neuroprotective activities. Although its mechanism of action is not fully understood, xaliproden appears to either mimic the effects of neurotrophins or stimulate their synthesis, thereby stimulating neuronal cell differentiation and proliferation and inhibiting neuronal cell death. The neuroprotective effect of this agent involves the activation of MAP kinase pathways via stimulation of the 5-HT1A receptor. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

(Other name for: crizotinib)

(Other name for: alprazolam)

(Other name for: methoxsalen)

(Other name for: rivaroxaban)

(Other name for: motexafin gadolinium)

(Other name for: capecitabine)

XELOX regimen  
A chemotherapy regimen consisting of capecitabine (Xeloda) and oxaliplatin used for the treatment of advanced-stage colorectal cancer. (NCI Thesaurus)

xenogeneic tyrosinase DNA vaccine  
A plasmid DNA vaccine, encoding an epitope of mouse tyrosinase, with potential antineoplastic activity. Administered via intramuscular electroporation, vaccination with xenogeneic tyrosinase DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) immune responses against melanoma cells that express tyrosinase, resulting in decreased tumor growth. . Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

(Other name for: corticorelin acetate)

(Other name for: denosumab)

(Other name for: rifaximin)

(Other name for: atrasentan hydrochloride)

An orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the receptor tyrosine kinases for vascular endothelial drowth factor (VEGF), c-kit, and platelet-derived growth factor (PDGF). In tumor models of breast carcinomas, gliomas, and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

A synthetic small-molecule inhibitor of checkpoint kinases 1 and 2 (Chk1 and Chk2) with potential antineoplastic activity. XL844 binds to and inhibits Chks 1 and 2, resulting in inhibition of cell cycle arrest, progressive DNA damage, inhibition of DNA repair, and, ultimately, tumor cell apoptosis. This agent also inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3), important mediators of tumor angiogenesis and lymphogenesis, respectively. In the presence of DNA damage or incomplete DNA replication, eukaryotic cells activate cell cycle checkpoints that temporarily halt the cell cycle to permit DNA repair or completion of DNA replication to take place. In the presence of extensive damage or absence of timely repair, these checkpoint-signaling pathways may also trigger a pathway that effects apoptosis. Normal functions of Chks involve the initiation of cell-cycle arrest and the up-regulation of transcription genes involved with DNA excision repair and dNTP synthesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

(Other name for: omalizumab)

(Other name for: ketoconazole)

(Other name for: enzalutamide)

(Other name for: lidocaine)

(Other name for: lidocaine)

(Other name for: paclitaxel poliglumex)

Back to TopBack to Top